Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits Δ(9)-tetrahydrocannabinol-induced central nervous system and heart rate effects in humans

AIM: Cannabinoid receptor type 1 (CB(1)) antagonists have been developed for the treatment of obesity and associated risk factors. Surinabant is a high affinity CB(1) antagonist in vitro. The aim of this study was to assess the magnitude of inhibition by surinabant of CNS effects and heart rate indu...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Klumpers, Linda E, Roy, Christine, Ferron, Geraldine, Turpault, Sandrine, Poitiers, Franck, Pinquier, Jean-Louis, van Hasselt, Johan G C, Zuurman, Lineke, Erwich, Frank A S, van Gerven, Joop M A
Format: Artigo
Langue:Inglês
Publié: Blackwell Science Inc 2013
Sujets:
Clinical Trials
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3703229/
https://ncbi.nlm.nih.gov/pubmed/23278647
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.12071
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires